The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Recent Advances in Targeting ROS1 in Lung Cancer
Open accessAbstract
&NA; ROS1 is a validated therapeutic target in NSCLC. In a phase I study, the multitargeted MET proto‐oncogene, receptor tyrosine kinase/anaplastic lymphoma kinase/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1‐rearranged NSCLCs and consequently gained approval by the United States Food and Drug Administration and by the European Medicines Agency in 2016. However, similar to other oncogene‐driven lung cancers, ROS1‐rearranged lung cancers treated with crizotinib eventually acquire resistance, leading to disease relapse. Novel ROS1 inhibitors and therapeutic strategies are therefore needed. Insights into the mechanisms of resistance to ROS1‐directed tyrosine kinase inhibitors are now beginning to emerge and are helping to guide the development of new ROS1 inhibitors. This review discusses the biology and diagnosis of ROS1‐rearranged NSCLC, and current and emerging treatment options for this disease. Future challenges in the field are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Self-citationGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Self-citationCeritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citationRET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Self-citationThe protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Self-citationGenomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationKinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Gainor, J. F., Varghese, A. M., Ou, S.-H. I., Kabraji, S., Awad, M. M., Katayama, R., Pawlak, A., Mino-Kenudson, M., Yeap, B. Y., Riely, G. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0318 · Cited by 604
Self-citationThe transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Self-citationDrilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Self-citationIdentifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Davies, K. D., Le, A. T., Theodoro, M. F., Skokan, M. C., Aisner, D. L., Berge, E. M., Terracciano, L. M., Cappuzzo, F., Incarbone, M., Roncalli, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0550 · Cited by 464
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A., Lipson, D., Otto, G., Brennan, T., Chung, C. T., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 455
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Self-citationMcDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Davies, K. D., & Doebele, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2851 · Cited by 373
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R., Shaw, A. T., Weiss, G. J., Tugnait, M., Narasimhan, N. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30392-8 · Cited by 352
Self-citationCrinò, L., Ahn, M.-J., De Marinis, F., Groen, H. J. M., Wakelee, H., Hida, T., Mok, T., Spigel, D., Felip, E., Nishio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5936 · Cited by 350
Self-citationNovel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Gainor, J. F., & Shaw, A. T. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0095 · Cited by 342
Self-citationWu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0758 · Cited by 321
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3701 · Cited by 301
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Rimkunas, V. M., Crosby, K. E., Li, D., Hu, Y., Kelly, M. E., Gu, T.-L., Mack, J. S., Silver, M. R., Zhou, X., & Haack, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3351 · Cited by 293
Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V., Wong, K. A., McTigue, M., Deng, Y.-L., Liu, W., Brooun, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420785112 · Cited by 267
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., Sakao, Y., Hida, T., & Yatabe, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8732 · Cited by 266
Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 264
Self-citationDifferential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Heuckmann, J. M., Balke-Want, H., Malchers, F., Peifer, M., Sos, M. L., Koker, M., Meder, L., Lovly, C. M., Heukamp, L. C., Pao, W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3260 · Cited by 261
Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
McCoach, C. E., Le, A. T., Gowan, K., Jones, K., Schubert, L., Doak, A., Estrada-Bernal, A., Davies, K. D., Merrick, D. T., Bunn, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2452 · Cited by 247
Resisting Resistance: Targeted Therapies in Lung Cancer
Lin, J. J., & Shaw, A. T. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 232
Self-citationSpectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230
Sonnenberg-Riethmacher, E., Walter, B., Riethmacher, D., Gödecke, S., & Birchmeier, C. (1996) · Genes & Development · doi:10.1101/gad.10.10.1184 · Cited by 219
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Birchmeier, C., Sharma, S., & Wigler, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9270 · Cited by 219
Testing for ROS1 in non-small cell lung cancer: a review with recommendations
Bubendorf, L., Büttner, R., Al-Dayel, F., Dietel, M., Elmberger, G., Kerr, K., López-Ríos, F., Marchetti, A., Öz, B., Pauwels, P., et al. (2016) · Virchows Archiv · doi:10.1007/s00428-016-2000-3 · Cited by 219
Woo, C. G., Seo, S., Kim, S. W., Jang, S. J., Park, K. S., Song, J. Y., Lee, B., Richards, M. W., Bayliss, R., Lee, D. H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw693 · Cited by 219
Charest, A., Lane, K., McMahon, K., Park, J., Preisinger, E., Conroy, H., & Housman, D. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10207 · Cited by 211
ALK,ROS 1 and NTRK 3 gene rearrangements in inflammatory myofibroblastic tumours
Yamamoto, H., Yoshida, A., Taguchi, K., Kohashi, K., Hatanaka, Y., Yamashita, A., Mori, D., & Oda, Y. (2016) · Histopathology · doi:10.1111/his.12910 · Cited by 208
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E. L., Koike, S., Shaw, A. T., Engelman, J. A., & Fujita, N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1385 · Cited by 201
Self-citationThe multifaceted roles of the receptor tyrosine kinase ROS in development and cancer
Acquaviva, J., Wong, R., & Charest, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.006 · Cited by 199
ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
Sholl, L. M., Sun, H., Butaney, M., Zhang, C., Lee, C., Jänne, P. A., & Rodig, S. J. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182960fa7 · Cited by 187
Suehara, Y., Arcila, M., Wang, L., Hasanovic, A., Ang, D., Ito, T., Kimura, Y., Drilon, A., Guha, U., Rusch, V., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0838 · Cited by 180
Cho, B. C., Kim, D.-W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., Park, K., Kim, S.-W., Ghosn, M., Ardizzoni, A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.005 · Cited by 171
Drilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 166
ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases
Yoshida, A., Kohno, T., Tsuta, K., Wakai, S., Arai, Y., Shimada, Y., Asamura, H., Furuta, K., Shibata, T., & Tsuda, H. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182758fe6 · Cited by 165
Charest, A., Wilker, E. W., McLaughlin, M. E., Lane, K., Gowda, R., Coven, S., McMahon, K., Kovach, S., Feng, Y., Yaffe, M. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1193 · Cited by 163
Facchinetti, F., Loriot, Y., Kuo, M.-S., Mahjoubi, L., Lacroix, L., Planchard, D., Besse, B., Farace, F., Auger, N., Remón, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0917 · Cited by 152
Matsushime, H., Wang, L., & Shibuya, M. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.8.3000-3004.1986 · Cited by 134
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
Lin, J. J., Ritterhouse, L. L., Ali, S. M., Bailey, M., Schrock, A. B., Gainor, J. F., Ferris, L. A., Mino-Kenudson, M. A., Miller, V. A., Iafrate, A. J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.004 · Cited by 133
Self-citationSong, A., Kim, T. M., Kim, D., Kim, S., Keam, B., Lee, S., & Heo, D. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1350 · Cited by 131
Shaw, A. T., Camidge, D. R., Engelman, J. A., Solomon, B., Kwak, E. L., Clark, J. W., Salgia, R., Shapiro, G. I., Bang, Y., Tan, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7508 · Cited by 129
Self-citationResistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128
Jun, H. J., Johnson, H., Bronson, R. T., de Feraudy, S. M., White, F. M., & Charest, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3990 · Cited by 120
Identification of ROS1 rearrangement in gastric adenocarcinoma
Lee, J., Lee, S. E., Kang, S. Y., Do, I., Lee, S., Ha, S. Y., Cho, J., Kang, W. K., Jang, J., Ou, S. I., et al. (2013) · Cancer · doi:10.1002/cncr.27967 · Cited by 120
Aisner, D. L., Nguyen, T. T., Paskulin, D. D., Le, A. T., Haney, J., Schulte, N., Chionh, F. J. M., Hardingham, J. E., Mariadason, J. M., Tebbutt, N. C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0479-t · Cited by 119
Characterization of an Activated Human ros Gene
Birchmeier, C., Birnbaum, D., Waitches, G. M., Fasano, O., & Wigler, M. H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3109 · Cited by 118
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J. M. S., Sweeney, R. T., Lai, E., Fitz, C. D. V., Forster, A. D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003464 · Cited by 117
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Davare, M. A., Vellore, N. A., Wagner, J. P., Eide, C. A., Goodman, J. R., Drilon, A. E. D. C., Deininger, M. W., O’Hare, T., & Druker, B. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515281112 · Cited by 117
Transient and locally restricted expression of the ros1 protooncogene during mouse development.
Sonnenberg, E., Gödecke, A., Walter, B., Bladt, F., & Birchmeier, C. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04937.x · Cited by 107
Birch, A. H., Arcand, S. L., Oros, K. K., Rahimi, K., Watters, A. K., Provencher, D. M., Greenwood, C. M. T., Mes‐Masson, A., & Tonin, P. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028250 · Cited by 98
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
Charest, A., Kheifets, V., Park, J., Lane, K. M., McMahon, K., Nutt, C. L., & Housman, D. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242741799 · Cited by 91
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Dziadziuszko, R., Le, A. T., Wrona, A., Jassem, J., Camidge, D. R., Varella‐Garcia, M., Aisner, D. L., & Doebele, R. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.001 · Cited by 83
Chong, C. R., Bahcall, M., Capelletti, M., Kosaka, T., Ercan, D., Sim, T., Sholl, L. M., Nishino, M., Johnson, B. E., Gray, N. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1601 · Cited by 81
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
Chen, Y., Hsieh, M., Wu, S., Chang, Y., Yu, C., Yang, J. C., Yang, P., & Shih, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.022 · Cited by 80
Tessarollo, L., Nagarajan, L., & Parada, L. F. (1992) · Development · doi:10.1242/dev.115.1.11 · Cited by 78
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Vaishnavi, A., Schubert, L., Rix, U., Marek, L. A., Le, A. T., Keysar, S. B., Glogowska, M. J., Smith, M. A., Kako, S. L., Sumi, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0109 · Cited by 76
Wiesweg, M., Eberhardt, W., Reis, H., Ting, S. C., Savvidou, N., Skiba, C., Herold, T., Christoph, D. C., Meiler, J., Worm, K., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.137 · Cited by 71
The human c-ros gene (ROS) is located at chromosome region 6q16----6q22.
Nagarajan, L., Louie, E., Tsujimoto, Y., Balduzzi, P. C., Huebner, K., & Croce, C. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.17.6568 · Cited by 70
Mouse Model for ROS1-Rearranged Lung Cancer
Arai, Y., Totoki, Y., Takahashi, H., Nakamura, H. K., Hama, N., Kohno, T., Tsuta, K., Yoshida, A., Asamura, H., Mutoh, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056010 · Cited by 61
Moro‐Sibilot, D., Faivre, L., Zalcman, G., Pérol, M., Barlési, F., Otto, J., Monnet, I., Cortot, A. B., Wislez, M., Léna, H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8065 · Cited by 48
Song, Z., Su, H., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.809 · Cited by 45
Characterization of an Activated Human ros Gene
Birchmeier, C., Birnbaum, D., Waitches, G. M., Fasano, O., & Wigler, M. H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3109-3116.1986 · Cited by 43
Zhu, V. W., Upadhyay, D., Schrock, A. B., Gowen, K. A., Ali, S. M., & Ou, S. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.013 · Cited by 42
Ou, S. I., Chalmers, Z. R., Azada, M. C., Ross, J. S., Stephens, P. J., Ali, S. M., & Miller, V. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.014 · Cited by 41
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M. S., Neal, J. W., Adrouny, A., Cherry, A. M., & Wakelee, H. A. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.008 · Cited by 36
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer
Liang, Y., Wakelee, H. A., & Neal, J. W. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.009 · Cited by 26
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
Dagogo‐Jack, I., & Shaw, A. T. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0179 · Cited by 25
Self-citationFelip, E., Bauer, T. M., Solomon, B., Besse, B., James, L., Clancy, J. S., Klamerus, K. J., Martini, J.-F., Abbattista, A., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.433 · Cited by 18
Self-citationGoto, K., Yang, J. C., Kim, D., Lü, S., Seto, T., Yang, J., Yamamoto, N., Ahn, M., Takahashi, T., Yamanaka, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9022 · Cited by 18
Cited by
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Self-citationOvercoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265
Metadata
- Authors
- Lin, J. J., & Shaw, A. T.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 12
- Issue
- 11
- Pages
- 1611-1625
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2748209653
- Cited by
- 261
- References
- 103
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.